Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Baseline distribution of demographic, clinical, and biochemical characteristics of the study population according to quartile groups of the distribution of values of serum osteoprotegerin levels. Serum OPG | 1st quartile (n = 356) | 2nd quartile (n = 355) | 3rd quartile (n = 356) | 4th quartile (n = 356) | P value: 25(OH) vitamin D (pg/mL) | 15.6 (10.6,20.7) | 16.8 (12.3,22.4) | 17.0 (12.7,24.8) | 15.8 (11.2,22.4) | 0.007

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Second, of the 1,423 patients, those aged under 50 years (n = 497) were excluded from our analysis for osteoporosis, because the target population for our study of osteoporosis prevalence was composed of individuals at higher risk of osteoporosis, namely men aged over 50 years and menopausal women, who are also expected to be aged over 50 years, as the mean age at menopause in Korean women is approximately 50 years [, ].

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study

Study design awaiting verification · PLoS ONE · 2016

Original publication title

Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study

Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Seung Hyeok Han; Kyu Hun Choi; Joongyub Lee; Dong Wan Chae; Kook-Hwan Oh; Curie Ahn; Soo Wan Kim; Representatives of the KNOW-CKD Investigator Group

© 2016 Kim et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Osteoprotegerin, a potent osteoclast activation inhibitor, decreases bone resorption and positively affects bone mineral density. This study examined the association between serum osteoprotegerin levels and bone loss in patients with chronic kidney disease, a condition associated with increased risk of mineral and bone disorders. The bone mineral densities of the lumbar spine, total hip, and femur neck were assessed by dual-energy X-ray absorptiometry; serum osteoprotegerin levels were measured at baseline for 1,423 patients enrolled in the prospective KoreaN cohort study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD).

Patients aged ≥50 years and with a T-score ≤: 2.5 were diagnosed as having osteoporosis. Multivariable linear regression analysis indicated independent association between serum osteoprotegerin levels and decreased bone mineral density in the lumbar spine (B:: 0.489, 95% confidence interval [CI]:: 0.883 to: 0.095, P = 0.015), and total hip (B:: 0.349, 95% CI:: 0.672 to: 0.027, P = 0.027). However, bone mineral density of the femur neck was not associated with serum osteoprotegerin levels in women. After adjustments, no independent association was found between serum osteoprotegerin levels and bone mineral density in men.

In multivariable logistic regression analysis, serum osteoprotegerin levels were associated with increased risk of osteoporosis in women (odds ratio [OR]: 4.72, 95% CI: 1.35 to 16.52, P = 0.015), but not in men (OR: 0.21; 95% CI: 0.04 to 1.31, P = 0.095). To summarize, in female patients with chronic kidney disease, increased serum osteoprotegerin levels were independently associated with decreased bone mineral density in the lumbar spine and total hip, and with increased risk of osteoporosis. Therefore, the measurement of serum osteoprotegerin concentration might be useful as a surrogate marker for determining bone loss in patients with chronic kidney disease, especially for women, although not so much for men.

Authors’ abstract

Osteoprotegerin, a potent osteoclast activation inhibitor, decreases bone resorption and positively affects bone mineral density. This study examined the association between serum osteoprotegerin levels and bone loss in patients with chronic kidney disease, a condition associated with increased risk of mineral and bone disorders. The bone mineral densities of the lumbar spine, total hip, and femur neck were assessed by dual-energy X-ray absorptiometry; serum osteoprotegerin levels were measured at baseline for 1,423 patients enrolled in the prospective KoreaN cohort study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD).

Patients aged ≥50 years and with a T-score ≤: 2.5 were diagnosed as having osteoporosis. Multivariable linear regression analysis indicated independent association between serum osteoprotegerin levels and decreased bone mineral density in the lumbar spine (B:: 0.489, 95% confidence interval [CI]:: 0.883 to: 0.095, P = 0.015), and total hip (B:: 0.349, 95% CI:: 0.672 to: 0.027, P = 0.027). However, bone mineral density of the femur neck was not associated with serum osteoprotegerin levels in women. After adjustments, no independent association was found between serum osteoprotegerin levels and bone mineral density in men.

In multivariable logistic regression analysis, serum osteoprotegerin levels were associated with increased risk of osteoporosis in women (odds ratio [OR]: 4.72, 95% CI: 1.35 to 16.52, P = 0.015), but not in men (OR: 0.21; 95% CI: 0.04 to 1.31, P = 0.095). To summarize, in female patients with chronic kidney disease, increased serum osteoprotegerin levels were independently associated with decreased bone mineral density in the lumbar spine and total hip, and with increased risk of osteoporosis. Therefore, the measurement of serum osteoprotegerin concentration might be useful as a surrogate marker for determining bone loss in patients with chronic kidney disease, especially for women, although not so much for men.

Publication and source details

Original title: Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study

Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Seung Hyeok Han; Kyu Hun Choi; Joongyub Lee; Dong Wan Chae; Kook-Hwan Oh; Curie Ahn; Soo Wan Kim; Representatives of the KNOW-CKD Investigator Group

PLoS ONE · 2016

Competing Interests: The authors have declared that no competing interests exist.

  • Conceptualization: CSK SWK.

  • Formal analysis: CSK.

  • Funding acquisition: CSK CA SWK.

  • Investigation: CSK EHB SKM.

  • Project administration: SWK CA.

  • Resources: SHH KHC JL DWC KHO CA.

  • Supervision: CSK SWK.

  • Writing: original draft: CSK.

  • Writing: review & editing: CSK EHB SKM SWK.

¶ Membership of the KNOW-CKD Investigator Group is provided in the Acknowledgments.

* E-mail: skimw@chonnam.ac.kr
© 2016 Kim et al2016Kim et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Research of Korea Centers for Disease Control and Prevention2013E3301600Ahn Curie the Korea Health Industry Development Institute (KHIDI)HI14C2084Kim Soo Wan the National Research Foundation of Korea (NRF)2016R1A2B4007870Kim Soo Wan the National Research Foundation of Korea (NRF)2015R1C1A1A01051769Kim Chang Seong Chonnam National University Hospital Institute for Biomedical ScienceCRI14008-1Kim Chang Seong This research was supported by grants 2011E3300300, 2012E3301100 and 2013E3301600 from Research of Korea Centers for Disease Control and Prevention, by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI14C2084), by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and future Planning (2016R1A2B4007870) and by the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2015R1C1A1A01051769), Chonnam National University Hospital Institute for Biomedical Science (CRI14008-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T19:53:48.964575+00:00

DOI: 10.1371/journal.pone.0166792 · PMC5113973